Mylan’s subsidiary wins FDA approval for generic Zerit capsules

US-based pharmaceutical company Mylan has announced that Matrix Laboratories, its India-based subsidiary in which it holds a 71.5% controlling interest, has received final approval from the FDA for its abbreviated new drug application for stavudine capsules USP, 15mg, 20mg, 30mg and 40mg.